The Global Alpha-1 Antitrypsin Deficiency (Aatd) Augmentation Therapy Market has been supported by late FDA endorsement for Prolastin-C. According to a report published by Fortune Business Insights, titled “AATD Augmentation Therapy: Global Analysis, Insights and Forecast, 2019-2026”, the market will be valued at US$ 1959.8 Mn by the end of 2026.
Browse Complete Report [email protected] https://www.fortunebusinessinsights.com/industry-reports/alpha-1-antitrypsin-deficiency-aatd-treatment-market-100189
The estimated rise in market value from its 2017 value of US$ 1115.5 Mn implies that the market will exhibit a CAGR of 5.9% in the foreacast period. Fortune Business Insights expects that factors such as regulatory approvals and improvements in augmentation therapies will drive the market in this period.
KEY PLAYERS COVERED
Some of the major companies that are present in the global alpha-1 antitrypsin deficiency treatment market are Grifols, CSL, Baxter, Kamada, Takeda, Abeona Therapeutics.
Some of the major companies that are present in the Global Alpha-1 Antitrypsin Deficiency Treatment Market are;
- Grifols S.A.
- CSL Limited
- Kamada Ltd.
- Takeda Pharmaceutical Company Limited
- Abeona Therapeutics Inc., and other players.
Grifols SA’s AlfaCare Program Has Had a Positive Impact on the Global Market
In November 2018, Grifols Sa introduced AlfaCare, a therapy program aimed at providing training and counselling to Alpha-1 Antitrypsin Deficiency (Aatd) Augmentation Therapy Market patients diagnosed with AATD. Grifols stated that with AlfaCare, it aims to encourage new habits in patients and help them manage their disease properly. Research studies have proven that a huge percentage of people diagnosed with AATD were unaware about the symptoms, effects, and ways to treat the disorder. AlfaCare was launched to overcome all such shortcomings and improve the quality of patient care, thereby ascertaining reduced fatality rate of AATD. Thus, AlfaCare has transformed AATD augmentation therapies worldwide and is likely to boost the global AATD augmentation therapy market in the forecast period.
Sample PDF Brochure @ https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/alpha-1-antitrypsin-deficiency-aatd-treatment-market-100189
By Drug Class
- Alpha-1 proteinase inhibitor
By Route of Administration
By Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Stores
North America to Dominate the Global Market
The growth in global alpha-1 antitrypsin deficiency treatment market is being driven by the emerging guideline for the treatment and diagnosis of alpha-1 antitrypsin deficiency treatment, potential pipeline products and rising awareness of alpha-1 antitrypsin deficiency. Furthermore, the rising prevalence of alpha-1 antitrypsin deficiency is expected to boost the global alpha-1 antitrypsin deficiency treatment market in the forecast period.
New Biological Approval for Prolastin C to Enable Growth of Global Market
In September 2017, Grifols received biologics license approval for Alpha-1 Proteinase Inhibitor to add a new liquid formulation to the currently licensed Prolastin C. The inclusion of this liquid may enable the launch of an additional alternative to the existing therapy. Clinical trials and proven efficacy have favored the approval for this product. With the latest addition to its product portfolio, Grifols will increase its stronghold in the global AATD augmentation therapy market.